| 4.705 -0.195 (-3.98%) | 08-28 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.81 | 1-year : | 6.79 |
| Resists | First : | 4.98 | Second : | 5.81 |
| Pivot price | 4.7 |
|||
| Supports | First : | 4.51 | Second : | 4.21 |
| MAs | MA(5) : | 4.76  |
MA(20) : | 4.67 |
| MA(100) : | 4.66 |
MA(250) : | 5.1 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 69.5 |
D(3) : | 67.6 |
| RSI | RSI(14): 52.9 |
|||
| 52-week | High : | 7.98 | Low : | 3.34 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ IVA ] has closed above bottom band by 49.6%. Bollinger Bands are 69.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 25 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.84 - 4.86 | 4.86 - 4.88 |
| Low: | 4.56 - 4.59 | 4.59 - 4.61 |
| Close: | 4.66 - 4.71 | 4.71 - 4.75 |
Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics. The firm primarily targets serious conditions such as non-alcoholic steatohepatitis (NASH), various forms of mucopolysaccharidoses (MPS), and other significant diseases. The company's most advanced experimental drug is Lanifibranor, which has successfully completed Phase IIb clinical trials for the treatment of NASH. Inventiva is also progressing with Odiparcil, an asset that has finished its Phase IIa clinical studies for addressing the MPS VI subtype disease. Beyond these lead candidates, Inventiva maintains a robust pipeline of earlier-stage research and development programs, notably in oncology and other therapeutic areas. The company has also established important strategic alliances, including a partnership with AbbVie focused on treatments for autoimmune diseases, and a collaboration with Boehringer Ingelheim International GmbH aimed at discovering novel therapies for idiopathic pulmonary fibrosis. Inventiva S.A. was established in 2011 and is headquartered in Daix, France.
Tue, 25 Aug 2026
Inventiva (IVA) Short Interest & Short Float | Updated Aug 2026 $IVA - MarketBeat
Sun, 23 Aug 2026
Full Year 2025 Inventiva SA Earnings Call Transcript - GuruFocus
Fri, 14 Aug 2026
IVA News | INVENTIVA SA - ADR (NASDAQ:IVA) - ChartMill
Wed, 05 Aug 2026
Inventiva: MASH Is Becoming A Combination Market Before Lanifibranor Arrives (NASDAQ:IVA) - Seeking Alpha
Fri, 17 Jul 2026
Cantor Fitzgerald initiates Inventiva stock with overweight rating - Investing.com
Wed, 15 Jul 2026
Inventiva (IVA) Announces Issuance of New EIB Warrants, Completes EIB Warrant Restructuring - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 236 (M) |
| Held by Insiders | 1.5792e+008 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 1,420 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.325e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -6 % |
| Return on Assets (ttm) | 710.6 % |
| Return on Equity (ttm) | -45.1 % |
| Qtrly Rev. Growth | 6.76e+006 % |
| Gross Profit (p.s.) | -98.8 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 7.40659e+006 |
| Qtrly Earnings Growth | -2.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -105 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -25.19 |
| Dividend | 0 |
| Forward Dividend | 2.2e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|